Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune

This page shows the latest Adaptimmune news and features for those working in and with pharma, biotech and healthcare.

New centre aims to Catapult UK into cell and gene therapy lead

New centre aims to Catapult UK into cell and gene therapy lead

It is already working with four biotechs working in so-called ‘advanced therapies’ - Autolus, Cell Medica, AdaptImmune and Freeline.

Latest news

  • GSK and Bayer strike new biotech cancer deals GSK and Bayer strike new biotech cancer deals

    GSK and Bayer strike new biotech cancer deals. Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines. ... GSK has agreed a $350m deal with US-based Adaptimmune to develop T-cell receptors to target a range of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific peptide-enhanced affinity receptor T cell immunotherapies in solid and haematological cancers.

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2).

  • Pharma deals during June 2014 Pharma deals during June 2014

    Of course the growth area within oncology is the immunological approach and GSK closed a $350m co-development and option deal with Adaptimmune. ... Adaptimmune develops TCR engineered T-cells and the agreement focuses on co-development around the cancer

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    Adaptimmune appoints Lawrence Alleva to its board. The former PwC partner will also chair its boardaudit committee. ... Adaptimmune has appointed former PwC partner Lawrence (Larry) Alleva to its board of directors as an independent, non-executive

  • Adaptimmune appoints former GSK executives Adaptimmune appoints former GSK executives

    Dr Amado said: “ I am pleased to be joining Adaptimmune at this exciting time. ... Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics